Mycobacterium tuberculosis (Mtb) restrains immune responses well enough to escape eradication but elicits enough immunopathology to ensure its transmission. Here we provide evidence that this host-pathogen relationship is regulated in part by a cytosolic, membrane-associated protein with a unique structural fold, encoded by the Mtb gene rv0431. The protein acts by regulating the quantity of Mtb-derived membrane vesicles bearing Toll-like receptor 2 ligands, including the lipoproteins LpqH and SodC. We propose that rv0431 be named "vesiculogenesis and immune response regulator." TLR2 | macrophages
Mycobacterium tuberculosis (Mtb) restrains immune responses well enough to escape eradication but elicits enough immunopathology to ensure its transmission. Here we provide evidence that this host-pathogen relationship is regulated in part by a cytosolic, membrane-associated protein with a unique structural fold, encoded by the Mtb gene rv0431. The protein acts by regulating the quantity of Mtb-derived membrane vesicles bearing Toll-like receptor 2 ligands, including the lipoproteins LpqH and SodC. We propose that rv0431 be named "vesiculogenesis and immune response regulator." TLR2 | macrophages M ycobacterium tuberculosis (Mtb) has coevolved with its human hosts from the time of our hominid ancestors (1, 2) . Millions of years of pathogenicity and an estimated cumulative toll of one billion human lives (3, 4) reflect Mtb's ability to elicit a balanced immune response. The host response to Mtb is vigorous enough to facilitate aerosol transmission by liquefying infected lung in 5-10% of those infected but is insufficient to sterilize infection in the remainder of the one-third of the human population that is estimated to carry Mtb in a latent form (5, 6) .
Mtb infection illustrates the complex balance between immunity and immunopathology that can dictate the host's fate in infectious disease (7, 8) . Unlike most bacterial pathogens, Mtb devotes the most conserved sequences in its genome to encode human T-cell epitopes (9) . Mtb activates macrophages, its primary niche, to a heightened antimicrobial and proinflammatory state but not maximally, as evidenced by the fact that knocking out particular genes in the host (10) (11) (12) or the pathogen (13) (14) (15) can lead to a greater level of macrophage activation (16) .
Recently, a forward genetic screen using a library of more than 10,000 loss-of-function transposon mutants of Mtb identified rv0431 as an endogenous regulator of Mtb's immunostimulatory potential (17) . Infection with Mtb rv0431:Tn led to markedly increased release of TNF-α, IL-12 p40, and IL-6 from primary mouse macrophages. Mtb rv0431:Tn grew normally in vitro but was attenuated in mice, suggesting that its proliferation may have been suppressed by a heightened host inflammatory or immune response. However, as with most other Mtb genes that have been found to restrain the host response, the mechanism by which rv0431 did so was unknown.
Mtb communicates with host cells by binding cellular receptors and by releasing products that do so. Toll-like receptor 2 (TLR2) is one prominent host-cell receptor through which Mtb and products such as the 19-kDa lipoprotein LpqH trigger macrophage responses (18) . Mtb secretes proteins through four known pathways: general secretion SecA1, general secretion SecA2, twin arginine transport (Tat), and type VII (19, 20) . Lipids released from Mtb can traffic out of infected macrophages in macrophage-derived exosomes (21) . Recently, Mtb was discovered to be among the various bacteria that can release membrane vesicles (MV) (22) . Mtb's MV are spheres, 60-200 nm in diameter, that are rich in immunomodulatory factors (22) , including LpqH, and another TLR2 agonist, SodC (23) . Little is known about how bacteria form and release MV, although the formation of MV may involve the packaging of proteins and lipoproteins secreted by one or more of the canonical pathways. To our knowledge, no genes have yet been identified that regulate the quantity or content of mycobacterial MV.
Here, we identify Rv0431 as a regulator of Mtb's MV. Through this means, Rv0431 exerts extensive control over the extent of TLR2-dependent stimulation of macrophages and over TLR2-dependent restriction of Mtb's growth in the host. Based on evidence presented below, we propose that rv0431 be named "vesiculogenesis and immune response regulator" (virR). Characterization of VirR as a protein that controls Mtb's MV and their inflammatory and immunostimulatory potential sets the stage for studies to explore the molecular machinery involved and the implications for immunization.
Results

VirR Deficiency Augments Responses of Mouse and Human Macrophages.
Earlier work demonstrated that the transposon disrupting virR had inserted between codons 121 and 122 (17) . However, it remained to be established whether the VirR protein was absent, truncated, or modified with a neo-C terminus, whether the mutant Significance Bacteria stimulate host cells in part via secreted products, some of which are packaged in membrane vesicles (MV). MV released by the major human pathogen Mycobacterium tuberculosis (Mtb) carry lipoprotein LpqH, a major agonist for host Toll-like receptor 2 (TLR2). This study identifies a gene, rv0431, which appears to regulate mycobacterial MV formation, and therefore we suggest it be named "vesiculogenesis and immune response regulator" (virR). This gene encodes a protein that includes a unique fold, as determined by NMR spectroscopy, and a disordered domain suggestive of participation in a higher-order complex. By restraining the release of most of the material released by Mtb that activates host cells through TLR2, VirR reduces Mtb's immunostimulatory potential and increases its virulence.
Mtb had broad effects on the mouse macrophage transcriptome, and whether the hyperstimulatory phenotype extended to human macrophages.
To address these questions, we began by raising polyclonal antisera to purified recombinant VirR. Immunoblot demonstrated that VirR migrated at ∼23 kDa, near its predicted molecular mass of 17 kDa, in lysates of WT Mtb but was undetectable in the lysates of the transposon mutant. Thus, the transposon insertion resulted in a null allele. Complementation with a WT allele of virR under the strong heat shock protein 60 (hsp60) promoter in an episomal plasmid led to overexpression (Fig. 1A) , which proved useful in subsequent experiments to evaluate a protein dose effect. Complementation reverted the hyperinflammatory phenotype of VirR-deficient Mtb in primary mouse bone marrow-derived macrophages (BMM) and reverted its attenuation in C57BL/6 mice (SI Appendix, Fig. S1 ).
We used global transcriptomic RNAseq profiles of uninfected BMM and BMM infected with WT or VirR-deficient Mtb to survey the extent of VirR's restriction of Mtb's immunostimulatory impact on macrophages. In three independent experiments at 8 h of infection at a multiplicity of infection (MOI) of 5, we observed increased levels of transcripts of 839 genes in response to WT Mtb infection. However, there was minimal differential impact on the macrophage transcriptome upon infection with VirR-deficient Mtb versus WT Mtb. Of the 839 genes, only 12 genes were up-regulated by ≥1.5-fold by infection with VirRdeficient Mtb relative to infection with WT Mtb (P ≤ 0.05) (SI Appendix, Table S1 ).These 12 genes did not include the genes encoding for cytokines and chemokines whose increased release from VirR-deficient infected macrophages was demonstrated by ELISA. The minimal differential impact on the macrophage transcriptome in response to infection with VirR-deficient Mtb might reflect that we analyzed the transcriptome at a single time point and/or suggest that posttranscriptional regulation played a role in increased expression of TNF-α and IL-12 p40.
Next, we tested the impact of VirR-deficient Mtb on primary human macrophages cultured at a physiologic tissue O 2 tension of 10% (24) . VirR-deficient Mtb hyperinduced TNF-α and IL-6 in the human cells in a dose-dependent manner ( Fig. 1 B and C) . The cytokine levels were elevated above those seen following infection with WT Mtb, even though the human macrophages sustained a far lower burden of VirR-deficient Mtb than WT Mtb (Fig. 1D) , with the difference amounting to 1 log 10 fewer cfu by day 9 postinfection. The macrophage monolayers were confluent after infection with either strain of Mtb, indicating that the reduced bacterial numbers did not result from fewer viable macrophages (SI Appendix, Fig. S2A ). Because the intracellular O 2 tensions may have been even lower than 10%, we tested the impact of O 2 tension on Mtb growth rate in axenic cultures. VirR-deficient Mtb replicated at the same rate as WT Mtb at 1% oxygen and at 20% O 2 (Fig. 1E) . Thus, the inability of VirRdeficient Mtb to replicate in human macrophages did not result from a greater dependence on O 2 . We tested whether VirR-deficient Mtb might be more susceptible than WT Mtb to acidification or to oxidative or nitrosative stress, using reported methods (25), but we found no differences in its susceptibility compared with WT Mtb (SI Appendix, Fig. S2 B-D) . Thus, VirR-deficient Mtb does not appear to be more sensitive than WT Mtb to several of the antimicrobial effectors of macrophages but does appear to activate human macrophages to a greater extent than WT Mtb.
VirR Regulates Release of Immunomodulatory Factors.
To analyze how VirR affects Mtb's ability to stimulate macrophages, we tested if medium conditioned by VirR-deficient Mtb would stimulate macrophages more potently than medium conditioned by WT Mtb. WT, VirR-deficient, and VirR-complemented Mtb were grown in 7H9 medium in the absence of detergent. Cellfree culture filtrate was concentrated using an ultrafiltration system with a 3-kDa cutoff and was added to BMM in graded doses. Culture filtrate from VirR-deficient Mtb proved to be far more potent than WT culture filtrate in stimulating mouse macrophages to produce TNF-α and IL-12 p40 ( Fig. 2A) and human macrophages to produce TNF-α and IL-6 (SI Appendix, Fig. S3 ).
To explore whether the increased release of immunostimulatory factors might represent leakage across compromised cell walls, we assessed bacterial morphology and sensitivity to SDS and lipophilic drugs and found no differences between VirRdeficient and WT Mtb (SI Appendix, Fig. S4 ). Furthermore, the protein concentrations of the culture filtrates of VirR-deficient, WT, and complemented strains were comparable (7, 7, and 8 μg/ mL, respectively). Thus, VirR-deficient Mtb had normal overall cell-wall integrity, and VirR deficiency did not lead to an overall increase in the amount of protein released by Mtb.
To distinguish increased release of immunostimulatory factors from decreased release of immunosuppressive factors-perhaps including VirR itself-we exposed BMM to mixtures of detergent-free culture filtrate from VirR-deficient and WT Mtb. Adding culture filtrate from VirR-deficient Mtb to filtrate from WT Mtb resulted in increased immunostimulation over an equal concentration of the latter filtrate alone (Fig. 2B) . Thus, it appeared that VirR-deficient Mtb released a greater quantity of immunostimulatory factors than WT Mtb, not a lesser quantity of inhibitory factors.
Next, we investigated whether VirR might suppress the production of immunostimulatory factors by Mtb at the transcriptional level, so that the immunostimulatory factors might be released to a greater extent when VirR was lacking. Earlier, we performed whole-genome transcriptomic analysis of macrophages infected with VirR-deficient Mtb; now we performed the analysis on the Mtb itself, again using RNAseq. No significant differences were detected between the transcriptomes of WT and VirR-deficient Mtb (Gene Expression Omnibus database accession no. GSE50050). We next investigated whether VirR might modulate specific secretory pathways. As noted, mycobacteria are known to secrete proteins by four defined mechanisms: SecA1, SecA2, Tat, and type VII. To investigate whether VirR might regulate these pathways, we used immunoblots to compare the quantities of a representative protein released by each pathway in the culture filtrate of VirRdeficient and WT Mtb. To ensure that the culture filtrate was not contaminated with cytosol from dying cells, we also assessed the levels of the cytosolic enzyme dihydrolipoamide acyltransferase (DlaT) (26, 27) . DlaT was detectable in cytosol but not in the culture filtrate. The culture filtrates of the two strains contained comparable levels of antigen 85B (Ag85B) and early secreted antigenic target of 6 kDa (ESAT6), indicating that VirR deficiency did not globally alter the SecA1 and type VII pathways (SI Appendix, Fig. S5 ). We could detect HspX and KatG, both SecA2 substrates, and BlaC, a Tat substrate, in the cytosol of each strain, where their levels were comparable. Both proteins were below the level of detection in culture filtrates from both strains. Thus, we could find no evidence that VirR deficiency globally enhanced secretion through SecA2 or Tat pathways. It is possible that VirR might regulate the release of individual substrates of these pathways other than those we measured.
In none of these studies could we detect VirR itself in the culture filtrate (SI Appendix, Fig. S5 ). In considering how VirR might function within the cell to suppress release of immunostimulatory factors outside the cell, we sought clues from VirR's relationship to the cell membrane and its structure.
Topological and Structural Features of VirR. Bioinformatic analysis of VirR's primary sequence identified no homologs outside of actinobacteria but predicted that VirR is a type I integral membrane protein, with its N terminus in the periplasm and C terminus in the cytoplasm. Immunoblotting subcellular fractions of WT Mtb with anti-VirR antibodies revealed a predominant association of VirR with the cell envelope fraction, which includes plasma membrane, periplasm, and outer membrane. However, we also detected VirR in the cytosolic fraction (Fig. 3A) . VirR's distribution was similar in WT Mtb and in VirR-deficient Mtb complemented with untagged VirR or with VirR bearing a FLAG tag at either terminus, although the expression of a FLAG-tag in the N terminus reduced expression of the protein (Fig. 3A) . If VirR has a single predominant subcellular localization, then its distribution in both cell envelope and cytosol fractions would suggest that VirR may be reversibly associated with the inner surface of the plasma membrane.
Because the experimental evidence challenged the bioinformatic prediction that VirR may be a single-pass transmembrane protein, we sought to define VirR's relationship to the plasma membrane by topologic studies with fusion proteins. Terminal fusion constructs coupled varying lengths of VirR with alkaline phosphatase (PhoA) or β galactosidase (LacZ) in their C termini (SI Appendix, form lacking the C-terminal 56 amino acids, and a more severely truncated form consisting only of residues 1-42 (that is, the first 20 amino acids and the predicted transmembrane domain) were each cloned as fusions with either of the reporters. The resulting six constructs were introduced individually into Mycobacterium smegmatis. All three strains transformed with PhoA constructs formed white colonies, suggesting that none of the constructs localized to the periplasm and that, instead, both termini of VirR were in the cytoplasm (SI Appendix, Fig. S6B ). As a positive control, M. smegmatis expressing Ag85B C-terminally fused with PhoA yielded blue colonies. All the LacZ fusion constructs gave rise to blue colonies, again suggesting that both termini of the protein were cytosolic. Taken together, the subcellular fractionation and topologic analyses suggested that VirR is located in the cytosol, where it is associated with the plasma membrane without crossing it.
Efforts to crystallize recombinant VirR were confounded by its seemingly unlimited solubility. This feature suggested that VirR contains an intrinsically disordered region. Such regions may acquire structure in the presence of a binding partner (28, 29) . Thus, we turned to NMR spectroscopy, using a truncated protein in which the highly hydrophobic stretch spanning amino acid residues 20-42 was deleted, along with the preceding 19 residues in the N terminus. The truncated protein, consisting of residues 42-164, was expressed in the pET28b vector system with a hexahistidine (His 6 ) tag in its N terminus to aid in purification from recombinant Escherichia coli. First, we explored the biologic properties of truncated VirR by complementing VirR-deficient Mtb with the same construct, checking its distribution in cell fractions, infecting BMM, and measuring their release of cytokines. Deletion of residues 1-42 led to a purely cytosolic distribution (SI Appendix, Fig. S6C ). The purely cytosolic form of VirR retained immunomodulatory capacity (SI Appendix, Fig. S6D ).
With the reassurance that the purely cytosolic, truncated form of VirR was functional, we resolved its structure at 0.9-Å resolution (Fig. 3B) . Consistent with its solution behavior, the first 35 amino acid residues in the N terminus of the truncated C-terminal two-thirds of the holoprotein were intrinsically disordered. The remainder of the protein, corresponding to residues 78-164 of the holoprotein, formed a globular structure with a unique fold. The fold consisted of a five-stranded β-sheet core flanked by two α-helices on one side and one α-helix on the other. Further details of the NMR analysis are shown in SI Appendix, Figs. S7-S11 and SI Appendix, Table S2 .
Proteins Associated with VirR. Given that VirR is predominantly cytosolic, albeit membrane associated, and contains a disordered domain suggestive of a binding partner, we considered that VirR might bind immunostimulatory factors within the cell and regulate their release. To investigate this possibility, we complemented the VirR-deficient strain with full-length FLAG-VirR with the C terminus tagged, confirmed that this complementation reverted the hyperstimulatory phenotype (SI Appendix, Fig.  S6C ), and used anti-FLAG antibody for coimmunoprecipitation. WT Mtb served as a negative control, because its VirR was untagged. Peptide mass fingerprinting of the immunoprecipitated proteins revealed VirR as the most abundant source of peptides. Three other proteins were relatively abundant in the anti-FLAG immunoprecipitate. Two are uncharacterized: Rv1488 and Rv0383c. The third was LpqH, the 19-kDa lipoprotein characterized as a major TLR2 agonist of Mtb (Fig. 4A) (18) . We confirmed the association of VirR with LpqH using coimmunoprecipitation of native VirR from WT Mtb with anti-VirR antibody (Fig. 4B) .
These experiments suggested that VirR plays an upstream regulatory role in modulating Mtb's impact on the macrophage response; that it does so via a noncanonical secretion mechanism or a postsecretion process; and that it might do so by virtue of what it binds. LpqH can exit Mtb through the SecA1 pathway (30) . Although the SecA1 substrate Ag85B was not overrepresented in the culture filtrate of VirR-deficient Mtb, we found that levels of LpqH were markedly higher in culture filtrate from VirR-deficient Mtb than in filtrate from WT Mtb (Fig. 4C) . This observation suggested that VirR might regulate the release of LpqH to the medium by a mechanism other than regulation of the SecA1 pathway.
VirR Regulates Mtb's Ability to Signal via TLR2. Because the culture filtrate of VirR-deficient Mtb was enriched in LpqH, a strong agonist of TLR2, we investigated the importance of TLR2 in mediating the hyperinflammatory properties of VirR-deficient culture filtrate and VirR-deficient Mtb itself. Compared with WT BMM, TLR2-knockout BMM treated with culture filtrate derived from VirR-deficient Mtb did not express enhanced levels of cytokines (Fig. 5A) . In two independent experiments, when we infected WT mice with ∼100 bacilli of the WT or VirR-deficient strains, VirR-deficient Mtb already was attenuated between days Fig. 4 . VirR is associated with LpqH, and culture filtrate derived from VirRdeficient Mtb is enriched in LpqH. (A) Lysates of FLAG-tagged VirR expressing Mtb and WT Mtb, grown to midlog phase, were immunoprecipitated with anti-FLAG antibody. The eluates were reduced, denatured, and subjected to SDS/PAGE, followed by mass spectrometry for identification of the binding partners. As indicated by the peak areas shown in the table, VirR was pulled down only in the FLAG-Rv0431 lysates, and LpqH was detected to a significantly greater extent in the FLAG-Rv0431 lysates, suggesting that the pulldown was anti-FLAG antibody specific. (B) To confirm binding of LpqH with VirR, native-coimmunoprecipitation was performed. WT and VirRdeficient Mtb lysates were immunoprecipitated with antiserum against VirR, and the eluates were immunoblotted with the same antiserum. The precleared lysates were loaded alongside eluates to confirm equal protein concentration between samples. (C) Culture filtrates and whole-cell lysates derived from WT, VirR-deficient, and VirR-complemented Mtb were immunoblotted with antiserum against LpqH. To ensure equal loading of culture filtrates among strains, samples were immunoblotted with antiserum against Ag85B. To ensure equal loading of lysates among strains and to rule out significant cell lysis, samples were immunoblotted with antisera against DlaT.
7 and 14 by 0.5 log 10 compared with WT Mtb. By day 21, the attenuation amounted to 1 log 10 , and this deficit was maintained through the 2 mo of observation. In contrast to a recent report (31) , the bacterial burden of WT Mtb was unaltered in TLR2-knockout mice compared with WT mice. However, the attenuation of VirR-deficient Mtb was substantially but not completely reversed in mice lacking TLR2 (Fig. 5B) . Thus, the attenuation of VirR-deficient Mtb in WT mice was mediated in part by an enhanced host response to TLR2 stimulation.
MV from VirR-Deficient Mtb Are Hyperinflammatory. Because Mtb MV were found to contain LpqH (22), we compared the LpqH content of MV from VirR-deficient and WT Mtb. Mtb cultures were grown in minimal 7H9 medium without detergent, and their MV were purified by sequential centrifugation and ultracentrifugation as described (22) . Compared with the MV fraction from WT Mtb, the MV fraction from VirR-deficient Mtb was indeed enriched in LpqH and also in SodC, another TLR2 agonist (Fig. 6A) . In contrast, the remainder of the culture filtrate after depletion of MV by ultracentrifugation contained much less LpqH and SodC, and the levels of these proteins in the soluble fraction were comparable in the two strains. To detect MV released into the culture fluid, we used the lipophilic probe, 1,6-diphenyl-1,3,5-hexatriene (DPH), which fluoresces in hydrophobic environments but not in aqueous environments (32) and has been used to detect MV in Borrelia burgdorferi culture supernatants (33) . By the DPH assay, VirR-deficient Mtb released 1.5-fold more lipid than WT Mtb, whereas the complemented strain released less than half as much as WT (Fig.  6B) . The ratios of protein to lipid in the MV fraction from WT and VirR-deficient Mtb were similar, suggesting that physiologic levels of VirR have a greater impact on the number of MV released than on the average protein content per MV.
Consistent with their greater content of TLR2 agonists, MV isolated from VirR-deficient Mtb were more stimulatory to BMM than MV from WT Mtb at equivalent protein concentrations, as assessed by TNF-α and IL-12 p40 concentrations in the supernatants (Fig. 6C) .
VirR Regulates Vesiculogenesis. The foregoing evidence suggested that VirR regulates some aspect of the production of MV, such as their number, size, or composition. We turned to scanning electron microscopy of VirR-deficient and WT Mtb and their isolated MV. On average, markedly more MV were visible on the surface of VirR-deficient Mtb than on WT or complemented strains (Fig.  7 A-C) , although the numbers on each strain were variable, and the visible portions of some bacteria appeared to be devoid of MV. A mean of 10, four, and two vesicles per cell were counted in VirR-deficient, WT, and complemented strains, respectively (Fig.  7D) . The differences between VirR-deficient strain and the other two strains were statistically significant (P < 0.01). There also appeared to be more filamentous, pilus-like structures on VirRdeficient Mtb than on WT and complemented strains (Fig. 7 A-C) .
Discussion
The studies presented here provide evidence that vesiculogenesis in Mtb is subject to genetic regulation. VirR controls vesiculogenesis in such a way as to blunt the activation of macrophages and the host's ability to restrict Mtb's proliferation. VirR does so in large part, but not exclusively, by diminishing the release of TLR2 agonists carried in MV.
Bacteria and archaea release vesicles with diverse bioactivities (34). For example, commensal Bacterioides fragilis packages (39, 40) . The lack of DegP, a periplasmic protease/chaperone in E. coli, resulted in an increased production of MV as a stress response, with an increased accumulation of DegP's substrate, misfolded outer membrane porins. Lack of E. coli's NlpA, an inner membrane-anchored lipoprotein, DsbA, a disulfide oxidoreductase, or BolA, a protein thought to regulate morphologic changes under stress conditions, resulted in hypovesiculation. Combining the deletion of degP with that of nlpA, dsbA, or bolA results in a growth defect in vitro (40) . In contrast, deletion of peptidoglycan-associated outer membrane proteins OprF and OprI in Pseudomonas aeruginosa results in hypervesiculation (39) . OprF has been shown to influence outer MV formation by modulating the Pseudomonas quinolone signal (39) . Bioinformatic searches based on homology modeling do not show any structural similarity between VirR and any of these proteins.
The mechanism by which VirR regulates vesiculogenesis remains to be defined. The identification of an intrinsically unstructured region of VirR suggests that VirR binds another protein through interactions with those residues. VirR's highly hydrophobic region is speculated to bind to the inner layer of the plasma membrane, but it may bind a protein with a hydrophobic surface. Coimmunoprecipitation led to the identification of three proteins associated with VirR: LpqH and two proteins about which almost nothing is known, Rv1488 and Rv0383c. We doubt that VirR restricts the content of LpqH in MV simply by binding LpqH and retaining it within the bacilli, because this process seems unlikely to account for VirR's regulation of the SodC content of MV, the abundance of MV, and the prevalence of filamentous structures. Moreover, LpqH localized predominantly in membrane and cell-wall fractions in both the WT and VirR-deficient strain, with no detectable difference in relative abundance between WT and VirR strains (SI Appendix, Fig. S11 ). Therefore, binding of VirR to LpqH is unlikely to play a role in regulation of vesiculogenesis. Taken together, these considerations suggest that VirR may function as part of a higher-order complex. We have no evidence for a direct interaction of VirR with SodC, but it is intriguing that SodC is encoded by rv0432 in the same operon as virR (rv0431).
Also requiring further study is the relationship between VirR and filamentous structures on Mtb. Filamentous structures were described on mycobacteria more than 40 y ago (41) . In recent work, such structures were characterized as laminin-binding pili comprised mainly of the protein Rv3312A, which is immunogenic in humans with tuberculosis and thus appears to be expressed in the host (42) . VirR may regulate the release of Rv3312A or a factor that participates in its polymerization.
This possibility leads to the question of the relation of MV formation in general and of VirR in particular to the SecA1, SecA2, Tat, and type VII secretory pathways. VirR may control the extent to which certain substrates for those pathways are degraded before they are secreted. Alternatively, VirR may regulate whether some substrates of the SecA1, SecA2, or Tat pathways are packaged in MV for transit through, or budding from, the outer membrane rather than being retained in the periplasm.
Likewise, it is remains to be clarified how MV formation by Mtb relates to exosome formation by macrophages containing Mtb (21, 43) . We speculate that extracellular Mtb use MV to communicate with the host, whereas MV released by intraphagosomal Mtb may become incorporated into macrophage exosomes. This two-step process of vesiculation would allow Mtb to influence not only the cell in which it resides but more distant host cells as well.
The involvement of TLR2 in mediating VirR-dependent immune modulation is consistent with the reported enrichment of TLR2 agonists in MV (22) and with the presence of TLR2 agonists in mycobacterial products recovered from exosomes shed by infected macrophages (21) . The partial restoration of virulence of VirR-deficient Mtb in mice lacking TLR2 suggested both that TLR2 is important in the host response to VirR-regulated processes and also that Mtb engages additional host signaling pathways in a manner influenced by VirR.
VirR regulates Mtb's stimulation of TLR2 in mouse macrophages and in mice, but we have not established to what extent the marked impact of VirR on the response of human macrophages to Mtb involves agonism of TLR2. A role for human TLR2 seems likely, given that engagement of TLR2 is important in inducing mycobactericidal factors, such as β-defensins, cathelicidin LL-37, granulysin, and ubiquitin-derived peptides (44) , in human macrophages (18) . It remains to be determined if these or other effectors contribute to the marked attenuation of VirRdeficient Mtb in human macrophages.
In a classic experiment by Jung and North (45), mice were immunized by infection with WT Mtb and then were cured with chemotherapy. When the mice were challenged again with WT Mtb, their protective immune response was manifest only 3 d earlier than in mice undergoing the challenge infection alone. In contrast, VirR-deficient Mtb activated the host in such a way that mice began to exert control over the infection as early as 7-14 d after inhaling ∼100 bacilli, rather than at 21-28 d, as seen with WT Mtb. This experiment raises the possibility that Mtb lacking VirR and additionally attenuated for safety (46) might be a more effective vaccine than Mtb bearing the additional attenuating mutations alone. Alternatively, cell-free, nonreplicative MV from VirR-deficient Mtb might be useful as an adjuvant or immunogen.
Materials and Methods
Assays for VirR topology and stress resistance of VirR-deficient Mtb, methods for transcriptomic analysis, and details of the NMR studies are described in SI Appendix. 
